Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Kiniksa Pharmaceuticals International
KNSA
Kiniksa Pharmaceuticals International
Reliance On Flagship Therapy Will Intensify Competition But Spur Optimism
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
25 Aug 25
Updated
25 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$38.00
11.7% undervalued
intrinsic discount
25 Aug
US$33.57
1Y
24.1%
7D
1.3%
Loading
1Y
24.1%
7D
1.3%
Author's Valuation
US$38.0
11.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$38.0
11.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-175m
934m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$933.6m
Earnings US$134.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
16.81%
Biotech revenue growth rate
11.91%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.16%
Calculation
US$134.06m
Earnings '28
x
27.91x
PE Ratio '28
=
US$3.74b
Market Cap '28
US$3.74b
Market Cap '28
/
80.13m
No. shares '28
=
US$46.68
Share Price '28
US$46.68
Share Price '28
Discounted to 2025 @ 7.16% p.a.
=
US$37.94
Fair Value '25
